Editas Medicine (NASDAQ:EDIT) Upgraded at JonesTrading

Editas Medicine (NASDAQ:EDIT) was upgraded by analysts at JonesTrading from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a $8.00 target price on the stock. JonesTrading’s target price suggests a potential upside of 203.61% from the company’s current price.

EDIT has been the subject of several other reports. TD Cowen reiterated a “buy” rating on shares of Editas Medicine in a research report on Monday. Chardan Capital reaffirmed a “buy” rating and issued a $3.50 price target on shares of Editas Medicine in a research note on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a research report on Wednesday, January 21st. Finally, Robert W. Baird set a $6.00 price objective on shares of Editas Medicine in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $5.30.

Editas Medicine Trading Up 13.6%

EDIT stock traded up $0.32 during trading on Tuesday, reaching $2.64. 2,955,657 shares of the stock were exchanged, compared to its average volume of 1,857,678. The firm has a market capitalization of $257.23 million, a price-to-earnings ratio of -1.10 and a beta of 2.16. The business has a 50 day moving average price of $2.01 and a 200-day moving average price of $2.57. Editas Medicine has a 1 year low of $0.91 and a 1 year high of $4.54.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Wednesday, March 11th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.21. The business had revenue of $24.74 million during the quarter, compared to analysts’ expectations of $8.77 million. Editas Medicine had a negative net margin of 430.84% and a negative return on equity of 277.29%. On average, research analysts anticipate that Editas Medicine will post -2.71 EPS for the current year.

Hedge Funds Weigh In On Editas Medicine

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its stake in Editas Medicine by 138.0% during the fourth quarter. Renaissance Technologies LLC now owns 3,039,778 shares of the company’s stock worth $6,232,000 after purchasing an additional 1,762,378 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Editas Medicine by 122.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock valued at $3,016,000 after purchasing an additional 1,430,000 shares in the last quarter. Geode Capital Management LLC increased its stake in Editas Medicine by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 2,284,740 shares of the company’s stock worth $4,685,000 after buying an additional 244,574 shares during the period. State Street Corp increased its stake in Editas Medicine by 2.6% during the 4th quarter. State Street Corp now owns 1,974,931 shares of the company’s stock worth $4,049,000 after buying an additional 49,887 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in Editas Medicine by 63.3% during the 3rd quarter. Two Sigma Investments LP now owns 1,584,155 shares of the company’s stock worth $5,497,000 after buying an additional 614,229 shares in the last quarter. 71.90% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Editas Medicine

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Q4 results beat expectations — Editas reported a narrower-than-expected loss (‑$0.06 EPS vs. consensus ‑$0.27) and revenue well above estimates, which traders view as strong operational progress for a clinical-stage biotech. Read More.
• Positive Sentiment: Clinical and regulatory progress — Management said EDIT-401 (LDL-C program) remains on track for IND/CTA submission by mid‑2026 and first-in-human trial with early proof-of-concept data expected by year-end 2026, giving investors a clearer near-term catalyst path. The company also reported cash runway into Q3 2027. Read More.
• Positive Sentiment: Analyst reaffirmation — Chardan Capital reaffirmed a Buy rating and a $3.50 price target, signaling analyst confidence and providing a visible upside reference for investors. Read More.
• Neutral Sentiment: Media coverage and momentum — Multiple outlets (MarketWatch, Yahoo, Investing.com) highlighted the beats and guidance, which can amplify intraday interest but are secondary to fundamentals and upcoming catalysts. Read More.
• Neutral Sentiment: Short-interest data appears unreliable — a dataset flagged large/NaN changes but shows zero reported short interest; this likely has no actionable impact unless clarified by exchanges or data providers.
• Negative Sentiment: Company remains unprofitable with negative margins and return on equity — despite the quarter’s beats, Editas is still loss-making and subject to typical biotech binary risks around clinical readouts and regulatory timelines. Read More.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.